More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Shire's Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent
Author: Joan McKenna
Shire’s Xiidra delivered Q2-2018 revenues of $100 million, a 75 percent increase over Q2-2017, the company reported July 31.
Dublin-based Shire launched Xiidra as a treatment for dry eye signs and symptoms in the US in September 2016.
Shire’s total product revenues were $3.8 billion, an increase of 6 percent over the same quarter in 2017. Royalties and other revenues decreased 28 percent to $111 million.
Shire also announced that it withdrew Xiidra’s marketing application in Europe from the decentralized procedure. The company plans to resubmit the application through the centralized procedure in Q4-2018.
Shire said its acquisition by Japan’s Takeda is on track for the first half of 2019, subject to shareholder approval of both companies and additional regulatory approvals.